for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Voyager Therapeutics Inc

VYGR.OQ

Latest Trade

3.15USD

Change

-0.04(-1.25%)

Volume

27,032

Today's Range

3.12

 - 

3.25

52 Week Range

3.05

 - 

12.65

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.19
Open
3.19
Volume
27,032
3M AVG Volume
10.02
Today's High
3.25
Today's Low
3.12
52 Week High
12.65
52 Week Low
3.05
Shares Out (MIL)
37.73
Market Cap (MIL)
120.35
Forward P/E
-1.18
Dividend (Yield %)
--

Next Event

Q2 2021 Voyager Therapeutics Inc Earnings Release

Latest Developments

More

Voyager Therapeutics Says Michael Higgins Will Assume Role Of Interim CEO

Voyager Therapeutics Receives FDA Clearance Of IND Application For Gene Therapy Candidate Vy-Htt01 For Treatment Of Huntington’S Disease

Voyager Therapeutics Reports Q4 And Full Year 2020 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company's pipeline consists of programs for CNS indications, including advanced Parkinson's disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington's disease; Friedreich's ataxia; frontotemporal dementia/Alzheimer's disease, and severe chronic pain. The Company's clinical candidate, VY-AADC01, is an adeno-associated virus (AAV) gene therapy product candidate, for the treatment of advanced Parkinson's disease. VY-AADC01 consists of the AAV2 capsid, which has been used in multiple AAV gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the aromatic L-amino acid decarboxylase (AADC) transgene. Its pipeline also includes VY-SOD101, VY-FXN01, VY-HTT01, VY-TAU01 and VY-NAV01.

Industry

Biotechnology & Drugs

Contact Info

75 Sidney St

CAMBRIDGE, MA

02139-4134

United States

+1.857.2595340

https://www.voyagertherapeutics.com/

Executive Leadership

Michael J. Higgins

Chairman of the Board, Interim President, Chief Executive Officer

Allison Dorval

Chief Financial Officer

Robert W. Hesslein

Senior Vice President, General Counsel

Glenn F. Pierce

Interim Chief Scientific Officer, Director

Steven M. Paul

Director

Key Stats

2.80 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.1K

2020

0.2K

2021(E)

0.0K
EPS (USD)

2018

-2.750

2019

-1.210

2020

0.980

2021(E)

-2.743
Price To Earnings (TTM)
3.09
Price To Sales (TTM)
0.75
Price To Book (MRQ)
0.88
Price To Cash Flow (TTM)
2.76
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
17.00
Return on Equity (TTM)
14.05

Latest News

Latest News

BRIEF-Voyager Therapeutics Reports Qtrly Loss Per Share $0.66

* VOYAGER THERAPEUTICS ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS AND CORPORATE UPDATES

BRIEF-Voyager Therapeutics Provides Update On The Restore-1 Parkinson’S Disease Trial

* VOYAGER THERAPEUTICS PROVIDES UPDATE ON THE RESTORE-1 PARKINSON’S DISEASE TRIAL

BRIEF-Voyager Therapeutics Announces Cancellation Of Presentation And Webcast At The Barclays Global Healthcare Conference

* VOYAGER THERAPEUTICS ANNOUNCES CANCELLATION OF PRESENTATION AND WEBCAST AT THE BARCLAYS GLOBAL HEALTHCARE CONFERENCE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up